1.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: B1931008, 3129K5-3303, NCT01232556
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: B1931022, NCT01564784
|
|
3.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: 2010-0991, NCT01371630
|
|
4.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: CMC-R-GEMOX, 2011-003849-18, NCT01562990
|
|
5.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 to 70
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: 2012-0265, NCT01664910
|
|
6.
|
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: UCL 11/0475, NCT01679119
|
|
7.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3129K2-1105, B1931003, NCT01055496
|
|
8.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: 2009-0872, NCT01134575
|
|
9.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: B1931010, 3129K6-1106, NCT01363297
|
|
10.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IOSI-LND-001, NCT01535989
|
Mobile | Español
